文献速递鼻科

变应性鼻炎患者冲击免疫治疗的临床观察与初步经济学研究

[Clinical observation and preliminary economic study of rush immunotherapy in patients with allergic rhinitis].
PubMed 文献 · Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi · 2022-01-01

研究纳入72例变应性鼻炎患者,按意愿分为冲击免疫治疗组35例与常规免疫治疗组37例,随访1年。两组疗效、安全性与成本-效果比相似,冲击免疫治疗组半年总有效率更高、脱落率更低、费用更高。

要点

  • 冲击免疫治疗组半年总有效率76.67%,高于常规免疫治疗组46.67%。
  • 剂量累加阶段两组全身不良反应发生率无显著差异。
  • 冲击免疫治疗组脱落率0,低于常规免疫治疗组13.51%。

核心结论

  • 冲击免疫治疗与常规免疫治疗均对变应性鼻炎有显著临床疗效,安全性与成本-效果比相似;冲击免疫治疗早期疗效更显著、患者依从性更高,值得临床推广和探索。

研究设计与样本

  • 研究纳入2019年10月至2020年6月在重庆医科大学附属第一医院耳鼻咽喉科确诊为变应性鼻炎并接受标准化尘螨特异性皮下免疫治疗的患者72例,男39例、女33例,年龄8~60岁。
  • 根据患者意愿分为冲击免疫治疗组35例与常规免疫治疗组37例,对所有研究对象随访1年。

主要发现

  • 治疗半年时冲击免疫治疗组总有效率76.67%,高于常规免疫治疗组46.67%(χ2=7.37,P=0.007)。
  • 剂量累加阶段两组全身不良反应发生率无显著差异(8.57%比8.10%,χ2=0.05,P=0.943)。
  • 冲击免疫治疗组脱落率0,低于常规免疫治疗组13.51%(χ2=5.08,P=0.024)。
  • 第1年治疗结束时冲击免疫治疗组费用高于常规免疫治疗组[(8 163.08±452.67)元比(7 385.87±369.92)元,t=-2.78,P=0.009]。
  • 两组成本-效果比无显著差异[(3 298.06±1 374.09)元/分比(3 154.38±1 532.51)元/分,t=-0.36,P=0.418]。

关键数值与推荐

  • 冲击免疫治疗组半年总有效率76.67%,常规免疫治疗组46.67%(χ2=7.37,P=0.007)。
  • 剂量累加阶段全身不良反应发生率冲击免疫治疗组8.57%,常规免疫治疗组8.10%(χ2=0.05,P=0.943)。
  • 脱落率冲击免疫治疗组0,常规免疫治疗组13.51%(χ2=5.08,P=0.024)。
  • 第1年治疗费用冲击免疫治疗组(8 163.08±452.67)元,常规免疫治疗组(7 385.87±369.92)元(t=-2.78,P=0.009)。
  • 成本-效果比冲击免疫治疗组(3 298.06±1 374.09)元/分,常规免疫治疗组(3 154.38±1 532.51)元/分(t=-0.36,P=0.418)。

临床怎么用

  • 作者认为冲击免疫治疗早期疗效更显著、患者依从性更高,值得临床推广和探索。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To observe the clinical efficacy, safety, compliance, and cost-effectiveness of rush immunotherapy (RIT) and conventional immunotherapy (CIT) in patients with allergic rhinitis (AR), so as to evaluate the clinical significance of CIT and preliminarily explore its economic value. Methods: A study was conducted on 72 AR patients who had received specific immunotherapy from Oct 2019 to Jun 2020 in the Department of Otorhinolaryngology, the First Affiliated Hospital of Chongqing Medical University, including 39 males and 33 females, aging 8 to 60 years. RIT or CIT was performed respectively according to the patients' wishes. There were 35 cases in the RIT group and 37 cases in the CIT group, all subjects were followed up for 1 year. Visual analysis scale (VAS) and effectiveness were used to evaluate the clinical efficacy. Systemic adverse reactions were used to assess safety. Failure rate was calculated to evaluate the compliance. The cost and cost-effectiveness ratio (CER) were conducted to evaluate the health economics preliminarily. Results: After half a year and one year's treatment, both RIT and CIT groups had significant clinical efficacy and RIT group had more significant clinical efficacy than CIT group at half a year (76.67% vs 46.67%, χ2=7.37, P=0.007). During the dose accumulation phase, there was no significant difference in the incidence of systemic adverse reactions between the two groups (8.57% vs 8.10%, χ2=0.05, P=0.943), while the drop-out rate in the RIT group was significantly lower than that in the CIT group (0 vs 13.51%, χ2=5.08, P=0.024). After one year, the costs in RIT group were significantly higher ((8 163.08±452.67) yuan vs (7 385.87±369.92) yuan, t=-2.78, P=0.009), while there was no statistical differences in CER between the two groups ((3 298.06±1 374.09) yuan/point vs (3 154.38±1 532.51) yuan/point, t=-0.36, P=0.418). Conclusions: Both RIT and CIT are beneficial for AR, and they have similar clinical efficacy, safety, and CER. RIT is more effective in the early stage, with higher patient compliance. Thus, RIT is worth promoting and exploring in clinic. 目的: 观察变应性鼻炎患者分别采用冲击免疫治疗(rush immunotherapy,RIT)和常规免疫治疗(conventional immunotherapy,CIT)的临床疗效、安全性、患者依从性及成本-效果比,以评价CIT的临床应用意义,并初步探讨其经济学价值。 方法: 选取2019年10月至2020年6月在重庆医科大学附属第一医院耳鼻咽喉科确诊为变应性鼻炎、接受标准化尘螨特异性皮下免疫治疗的患者共72例,其中男39例,女33例,年龄8~60岁。根据患者意愿,分别行RIT或CIT,其中RIT组35例,CIT组37例,对所有研究对象进行为期1年的随访观察。采用视觉模拟量表评分、疗效评估和药物评分评价其临床疗效,采用全身不良反应发生率评价其安全性,采用脱落率评价其患者依从性,采用治疗成本和平均成本-效果比(cost-effectiveness ratio,CER)初步评价其药物经济学价值。 结果: 在治疗半年和1年时,RIT组和CIT组均有显著疗效,且RIT组较CIT组在半年时总有效率更高(76.67%比46.67%,χ2=7.37,P=0.007)。在剂量累加阶段,两组患者全身不良反应发生率无显著差异(8.57%比8.10%,χ2=0.05,P=0.943),而RIT组治疗脱落率显著低于CIT组(0比13.51%,χ2=5.08,P=0.024)。在第1年治疗结束时,RIT组治疗费用高于CIT组[(8 163.08±452.67)元比(7 385.87±369.92)元,t=-2.78,P=0.009],而两组CER无显著差异[(3 298.06±1 374.09)元/分比(3 154.38±1 532.51)元/分,t=-0.36,P=0.418]。 结论: RIT和CIT均能获得显著临床疗效,均具有良好安全性,单位疗效所花费平均治疗成本相似。RIT早期疗效更显著,患者依从性更高,值得临床推广。.

来源:Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Shen Y, Ke X, Yang YC, et al. [Clinical observation and preliminary economic study of rush immunotherapy in patients with allergic rhinitis]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022. PMID: 36707955. doi:10.3760/cma.j.cn115330-20220104-00003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。